Associated Papers
Concurrent EGFR L858R and K860I mutations: PCR-negative but NGS-positive alterations that respond to EGFR inhibitors in non-small cell lung cancer.
Shi H et al.
Journal of Thoracic Disease, 2025
Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations.
Li Y et al.
Hereditary Cancer in Clinical Practice, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.
Montella T et al.
Jco Global Oncology, 2023
Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers.
Wen H et al.
Jama Network Open, 2023
Germline EGFR mutations in lung cancer (Review).
Liu M et al.
Oncology Letters, 2023
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.
Chamorro DF et al.
Targeted Oncology, 2023
A pilot study of on-site evaluation as external quality assessment for ISO 15189 accreditation of laboratories performing next-generation sequencing oncology tests.
Ravzanaadii M et al.
Journal of Clinical Laboratory Analysis, 2023
Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
Casula M et al.
International Journal of Molecular Sciences, 2023
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes.
Zhao W et al.
Bmc Medicine, 2023
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Investigation of EGFR mutations in non-small cell lung cancer usually undetectable by PCR methods.
Matsubara T et al.
Molecular and Clinical Oncology, 2022
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses.
Koopman B et al.
Cancers, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study.
Lin X et al.
Frontiers in Oncology, 2021
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ et al.
Scientific Reports, 2019
Challenges of Providing Concordant Interpretation of Somatic Variants in Non-Small Cell Lung Cancer: A Multicenter Study.
Gao P et al.
Journal of Cancer, 2019
Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients.
Liu J et al.
Drug Design, Development and Therapy, 2019
Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Ghafoor Q et al.
Pathology Oncology Research : Por, 2018
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.
Williams HL et al.
Virchows Archiv : an International Journal of Pathology, 2018
Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C et al.
Molecular Medicine Reports, 2018
EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes.
Yudong S et al.
Thoracic Cancer, 2018
Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy.
Aggarwal S et al.
Indian Journal of Cancer, 2017
Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.
Harvey NT et al.
Pathology, 2016
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2015
Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase.
Paladino A et al.
Journal of Chemical Information and Modeling, 2015
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X et al.
Amino Acids, 2014
KRAS, EGFR, PDGFR-α, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE).
Veits L et al.
Diagnostic Pathology, 2014
Lack of mutations in protein tyrosine kinase domain coding exons 19 and 21 of the EGFR gene in oral squamous cell carcinomas.
Mehta DT et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2014
EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice.
Gahr S et al.
British Journal of Cancer, 2013
EGFR mutation status in brain metastases of non-small cell lung carcinoma.
Burel-Vandenbos F et al.
Journal of Neuro-oncology, 2013
Drug resistance missense mutations in cancer are subject to evolutionary constraints.
Friedman R
Plos One, 2013
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K et al.
Journal of Clinical Pathology, 2012
Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area.
Hsieh CH et al.
Head & Neck, 2011
Predicting the functional impact of protein mutations: application to cancer genomics.
Reva B et al.
Nucleic Acids Research, 2011
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
Epidermal growth factor receptor mutation in gastric cancer.
Liu Z et al.
Pathology, 2011
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.
Peraldo-Neia C et al.
Bmc Cancer, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
Pirker R et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2010
Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies.
Do H et al.
Molecular Cancer, 2009
EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan.
Huang SF et al.
Head & Neck, 2009
Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K et al.
Lung Cancer (amsterdam, Netherlands), 2008